US 7,459,568 B2Granted

Alpha crystalline form of strontium ranelate

AssigneeLes Laboratoires Servier

InventorsStéphane Horvath, Isabelle Demuynck, Gérard Damien

Life of this patent

Estimating the term…

Abstract

Alpha crystalline form of strontium ranelate of formula (I): characterized by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in the treatment of osteoporosis and arthrosis.

Claims5

Dependent claims

The alpha crystalline form of the compound of formula (I):

wherein the compound has a water content of from 22 to 24% and exhibits essentially the following powder X-ray diffraction diagram expressed in terms of ray position (Bragg's angle 2 theta, expressed in degrees), ray height (expressed in counts), ray area (expressed in counts×degrees), ray width at half-height (“FWHM”, expressed in degrees) and interplanar distance d (expressed in Å):
Surface
Angle 2 theta
Height
(counts ×
FWHM
Interplanar
Ray no.
(degrees)
(counts)
degrees)
(degrees)
distance (Å)
1
7.6
4527
448
0.1004
11.649
2
8.0
1438
142
0.1004
11.069
3
8.3
3522
349
0.1004
10.642
4
8.6
11347
1123
0.1004
10.272
5
8.9
7332
726
0.1004
9.889
6
11.0
1047
104
0.1004
8.072
7
11.3
1655
164
0.1004
7.840
8
12.0
2186
216
0.1004
7.355
9
13.2
2887
381
0.1338
6.703
10
13.5
1705
169
0.1004
6.557
11
14.1
154
30
0.2007
6.275
12
14.7
803
79
0.1004
6.035
13
14.9
1346
178
0.1338
5.942
14
15.8
1556
154
0.1004
5.613
15
16.0
3339
441
0.1338
5.527
16
16.7
1845
183
0.1004
5.308
17
17.3
2835
281
0.1004
5.127
18
17.6
1252
124
0.1004
5.049
19
18.0
2183
216
0.1004
4.939
20
19.2
2303
228
0.1004
4.622
21
19.8
1298
128
0.1004
4.475
22
20.3
788
78
0.1004
4.373
23
20.6
1039
103
0.1004
4.317
24
21.1
882
116
0.1338
4.211
25
21.7
390
38
0.1004
4.103
26
22.3
1919
253
0.1338
3.990
27
22.7
1805
179
0.1004
3.923
28
23.0
4043
467
0.1171
3.861
29
23.5
650
86
0.1338
3.792
30
24.0
8677
1002
0.1171
3.711
31
24.7
229
30
0.1338
3.600
32
25.1
1246
164
0.1338
3.543
33
25.6
1659
219
0.1338
3.473
34
25.9
1773
175
0.1004
3.442
35
26.3
695
69
0.1004
3.385
36
26.6
401
46
0.1171
3.355
37
27.0
2800
370
0.1338
3.300
38
27.6
1415
140
0.1004
3.230
39
28.0
3250
429
0.1338
3.186
40
28.4
1513
250
0.1673
3.144
41
29.1
1456
144
0.1004
3.068
42
29.6
1943
192
0.1004
3.022
43
30.1
3637
540
0.1506
2.967
44
30.5
707
117
0.1673
2.929
45
30.9
596
59
0.1004
2.897
46
31.8
577
76
0.1338
2.816
47
32.0
1080
107
0.1004
2.796
48
32.5
512
51
0.1004
2.756
49
32.9
1268
167
0.1338
2.726
50
33.4
1180
117
0.1004
2.685.

310 more elements

Dependencies are inferred from the claim text.

Facts

Application: 11/140,822Filed 31 May 2005
Priority: FR 04 1033530 Sep 2004
Published: US 2006/0069271 A130 Mar 2006
Granted: 2 Dec 2008
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

C07D 333/38
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
A61P 19/00
Drugs for skeletal disorders
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 19/10
For bone diseases, e.g. rachitism, Paget's disease: for osteoporosis

Family

US 2006/0069271 A1Pre-grant publication · published 30 Mar 2006
US 7,459,568 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The alpha crystalline form of the compound of formula (I):

wherein the compound has a water content of from 22 to 24% and exhibits essentially the following powder X-ray diffraction diagram expressed in terms of ray position (Bragg's angle 2 theta, expressed in degrees), ray height (expressed in counts), ray area (expressed in counts×degrees), ray width at half-height (“FWHM”, expressed in degrees) and interplanar distance d (expressed in Å):
Surface
Angle 2 theta
Height
(counts ×
FWHM
Interplanar
Ray no.
(degrees)
(counts)
degrees)
(degrees)
distance (Å)
1
7.6
4527
448
0.1004
11.649
2
8.0
1438
142
0.1004
11.069
3
8.3
3522
349
0.1004
10.642
4
8.6
11347
1123
0.1004
10.272
5
8.9
7332
726
0.1004
9.889
6
11.0
1047
104
0.1004
8.072
7
11.3
1655
164
0.1004
7.840
8
12.0
2186
216
0.1004
7.355
9
13.2
2887
381
0.1338
6.703
10
13.5
1705
169
0.1004
6.557
11
14.1
154
30
0.2007
6.275
12
14.7
803
79
0.1004
6.035
13
14.9
1346
178
0.1338
5.942
14
15.8
1556
154
0.1004
5.613
15
16.0
3339
441
0.1338
5.527
16
16.7
1845
183
0.1004
5.308
17
17.3
2835
281
0.1004
5.127
18
17.6
1252
124
0.1004
5.049
19
18.0
2183
216
0.1004
4.939
20
19.2
2303
228
0.1004
4.622
21
19.8
1298
128
0.1004
4.475
22
20.3
788
78
0.1004
4.373
23
20.6
1039
103
0.1004
4.317
24
21.1
882
116
0.1338
4.211
25
21.7
390
38
0.1004
4.103
26
22.3
1919
253
0.1338
3.990
27
22.7
1805
179
0.1004
3.923
28
23.0
4043
467
0.1171
3.861
29
23.5
650
86
0.1338
3.792
30
24.0
8677
1002
0.1171
3.711
31
24.7
229
30
0.1338
3.600
32
25.1
1246
164
0.1338
3.543
33
25.6
1659
219
0.1338
3.473
34
25.9
1773
175
0.1004
3.442
35
26.3
695
69
0.1004
3.385
36
26.6
401
46
0.1171
3.355
37
27.0
2800
370
0.1338
3.300
38
27.6
1415
140
0.1004
3.230
39
28.0
3250
429
0.1338
3.186
40
28.4
1513
250
0.1673
3.144
41
29.1
1456
144
0.1004
3.068
42
29.6
1943
192
0.1004
3.022
43
30.1
3637
540
0.1506
2.967
44
30.5
707
117
0.1673
2.929
45
30.9
596
59
0.1004
2.897
46
31.8
577
76
0.1338
2.816
47
32.0
1080
107
0.1004
2.796
48
32.5
512
51
0.1004
2.756
49
32.9
1268
167
0.1338
2.726
50
33.4
1180
117
0.1004
2.685.

310 more elements

Facts

Application

11/140,822Filed 31 May 2005

Priority

FR 04 1033530 Sep 2004

Published

US 2006/0069271 A130 Mar 2006

Granted

2 Dec 2008

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

C07D 333/38
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
A61P 19/00
Drugs for skeletal disorders
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 19/10
For bone diseases, e.g. rachitism, Paget's disease: for osteoporosis